glp-1 receptor agonist weight loss agonists – How injections work Anti-obesity drugs are closing the

Concurrent use with an insulin secretagogue or insulin may raise the risk of hypoglycemia

Analysis of the gut microbiome revealed beneficial bacteria was significantly enriched, while the bad bacteria significantly decreased

This dietary intervention trial received ethical approval from the Quadram Institute Bioscience Human Research Governance Committee (QIB01/2024) and the South East Scotland Research Ethics Committee (24/SS/0047) and is registered at ClinicalTrials.gov (NCT06518343)

Research also suggests it may support gastrointestinal health, reduce NSAID-related damage, and aid recovery from various tissue injuries